หน้าแรก เว็บบอร์ด หาเพื่อน Chat หาเพื่อน Line หาเพื่อน Skype โปรโมชั่น Pic Post ตรวจหวย ควิซ เกมถอดรหัสภาพ Page คำนวณ คำคม วิดีโอ สเปซ เกม Play ไดอารี่ อัลบั้ม แต่งรูป Glitter
 
ติดต่อเว็บไซต์ลงโฆษณาลงข่าวประชาสัมพันธ์แจ้งเนื้อหาไม่เหมาะสมเงื่อนไขการให้บริการ
 
Login เข้าสู่ระบบ สมัครสมาชิก
 
CD40 Combination Treatment Can Shrink Pancreatic Tumors
21:57 - 13 มกราคม 2563

Atlanta-New combination of immunotherapy and chemotherapy for pancreatic cancer results in tumor shrinkage in most evaluable patients-20 of 24 in interim analysis of phase 1b trial data. Early detection offers hope that this strategy involving anti cd40 antibody, checkpoint inhibitors and standard chemotherapy could effectively treat the country's third deadly cancer. Researchers at the University of Pennsylvania's Abramson Cancer Center will present their findings at a clinical trial plenary meeting of the American Cancer Research Association 2019 Annual Meeting in Atlanta today (Abstract # 8060). Ongoing research is being conducted in collaboration with the Parker Cancer Immunotherapy Institute and other member institutions and partners.

 

"These findings give us clues that this new and innovative combination therapy is effective against pancreatic cancer," said the study's co-lead author, Mark H. O'Hara, an assistant professor of hematology and oncology at the University of Pennsylvania. "Although only time and further research will really tell, our data is a reason for optimism." O'Hara will hold a plenary session at 12:45 pm at the Marcus Auditorium in Bldg A-GWCC.

 

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, killing more Americans each year than any type of cancer other than lung and colorectal cancer. Although it accounts for only about 3% of new cancer cases, it causes more than 7% of cancer deaths, and only 8.5% of patients survive for 5 years. Previous studies have shown that PD-1 inhibitors are not effective against PDAC itself, but preclinical data have shown that combining PD-1 inhibitors with antibodies that target different antigens (called cd40 agonist) can trigger immune responses.

 

For this study, patients with previously untreated metastatic PDAC received a combination of four different therapies. Each patient received gemcitabine and nab-paclitaxel, which are standard therapeutic chemotherapies, as well as an experimental antibody targeting CD40 called APX005M. Half of the patients also received the PD-1 inhibitor nivolumab. As of the date of the interim analysis, 20 of the 24 patients (83%) saw their tumors shrink. Overall, although most patients experienced treatment side effects, they were expected and manageable, and some patients continued treatment for more than a year, which also indicates that the combination treatment can produce a durable response.

 

"Seeing patients continue treatment during this time period really makes us hope that this combination approach is promising, especially when you consider stage 4 pancreatic cancer with a median survival of only 2 to 6 months," senior author Robert H. Vonderheide said. , MD, DPhil, director of Abramson Cancer Center and member researcher of Parker Institute. Vonderheide previously led the first human clinical trial of APX005M reported in 2017, which enabled current research.

 

The Parker Institute holds research applications for new drugs from the US Federal Drug Administration. Patients in the trial were treated at seven Parker member institutions, leveraging unique capabilities to develop faster and more effective clinical studies.

 

"This research represents the first example of our unique collaboration model. We used to bring together partners from academia, pharmaceutical companies and biotechnology companies to help accelerate the translation of laboratory research results into efficient, Impact of the clinical trial process. Need, "said Dr. Ramy Ibrahim, chief medical officer of the Parker Cancer Immunotherapy Institute. "Based on these early but promising discoveries, we are excited to see the results of the next phase of the study."

คอมเม้นต์
กรุณา "เข้าสู่ระบบ" ก่อนคอมเม้นต์
ผู้เขียน
บล็อกโปรด